As a sixteen-year gastric cancer survivor, Chef Hans Rueffert shares a personal message about the importance of your support as we "Come Together for a Cure."
Foundation Awards New Grants to Researchers Pursuing Novel Approaches in Gastric Cancer
The biggest challenge facing researchers who have exciting but unproven ideas for fighting gastric cancer is raising the funds they need to complete vital early-stage studies. The Gastric Cancer Foundation is committed to addressing this funding gap, in the hopes of contributing to research that could inspire novel treatments.

Towards that end, the Foundation has awarded two new $100,000 research grants. One will go to the lab of Timothy Wang, M.D., professor at Columbia University Vagelos College of Physicians and Surgeons, which is focused on enhancing immuno-oncology treatments by targeting specific myeloid cells. Another grant was awarded to a team led by Nina Salama, Ph.D., professor at Fred Hutchinson Cancer Research Center, which will investigate the role of Fusobacterium nucleatum in gastric cancer. 
Gesundheit Superfoods: Whole Grains

Chef Hans Rueffert always likes to have whole grains at the ready in his kitchen. While he makes a nourishing mixed grains cereal, Hans discusses with registered dietitian, Dr. Ellen Steinberg the wonderful blood regulating (among other things) advantages of high fiber foods.
Research Roundup
Some of the most exciting recent developments in gastric cancer research involved drugs that boost the immune system.

A novel drug that inhibits the immune checkpoint PD-1 showed positive safety and efficacy in a phase 2 clinical trial in patients with microsatellite instability-high or mismatch repair deficient solid tumors, including gastric cancer.

The PD-1 inhibitor Opdivo combined with paclitaxel showed anti-tumor activity in a phase 1/2 study of gastric cancer patients with a variety of tumor markers, including Epstein-Barr virus, MSI-high and PD-L1. The treatment used in the second-line setting produced a median overall survival rate of 11 months.

A combination of the targeted drug Herceptin, chemotherapy and the PD-1 blocker Keytruda significantly increased the response rate in patients with HER2-positive gastric cancer, as compared to Herceptin and chemo alone.
Quick Links to Resources
Special Thanks to Our
National Sustaining Sponsors
Spread the word. Share the Gastric Cancer Foundation Newsletter.